SpaceX IPO vs. Rocket Lab: Which Space Economy Stock Is the Better Buy?

SpaceX is cited at a $1.77 trillion IPO valuation, implying a very high bar for future upside, while Rocket Lab is presented as the higher risk-reward alternative. Rocket Lab reported 2025 revenue of about $602 million, up 38% year over year, with a backlog above $2 billion and Q1 2026 revenue of $200 million, but it remains unprofitable and Neutron has been delayed. The article is largely an investment comparison and valuation discussion rather than new market-moving news.

Analysis

The market is implicitly treating space as a winner-take-most platform business, but the valuation spread argues the opposite setup for returns. A near-$2T private market cap creates a very high hurdle for multiple expansion, while the smaller listed ecosystem still has multiple shots on goal: launch, satellite hardware, software, and government services. That means the better risk-adjusted exposure is not “the best company,” but the company with the most operating leverage to incremental contract wins and a credible path to re-rate from execution, not perfection.

The second-order effect is that a premium on the leader can actually help the tier-two players by forcing customers and agencies to diversify supplier exposure. In defense and sovereign space procurement, single-vendor dependence becomes a budget and security issue; that dynamic can extend contract duration and expand backlog quality for alternate providers. The key tell over the next 6-18 months is whether larger launch demand is broadening beyond the dominant incumbent and whether supply chain bottlenecks in propulsion, avionics, and spacecraft subsystems favor vertically integrated peers.

The biggest catalyst-risk mismatch sits in development timelines. If the next-generation rocket slips again, the equity story remains anchored to smaller launch and services economics, which are decent but not enough to justify aggressive multiple expansion. Conversely, even one clean milestone on a larger reusable vehicle could reframe the company from “niche provider” to “credible second source,” which tends to drive both backlog conversion and valuation uplift before revenue fully inflects. The market is likely underpricing how much optionality lives in that transition versus the near-zero optionality embedded in a fully priced monopoly-like asset.

The contrarian takeaway is that the crowded trade may be the obvious winner, not the overlooked operator. Investors are extrapolating brand strength and strategic dominance into unbounded upside, but the more interesting setup is a differentiated industrial-growth story with defense adjacency and multiple monetization paths. That profile usually outperforms when execution is merely good rather than flawless.

Key Decisions for Investors

• Long RKLB over 6-12 months as a selective growth/defense compounder; target a position into weakness ahead of major launch or program milestones. Risk/reward: asymmetric if Neutron de-risks, but size modestly because delays can compress the multiple 20-30%.
• Pair trade: long RKLB / short a basket of expensive private-market space proxies or satellite-service hype names if accessible; thesis is valuation mean reversion from ‘story premium’ to cash-flow credibility over the next 2-4 quarters.
• Avoid initiating exposure to any SpaceX-linked public-market expression at current implied valuation levels; if forced, use call spreads rather than outright longs to cap downside from disappointment in growth normalization.
• Use event-driven sizing around Neutron-related catalysts: buy 1-2 months before launch windows or major contract awards, trim 25-50% into positive milestone prints, and reload on any post-event pullback.
• If looking for cleaner defense-linked exposure, pair RKLB with an aerospace/defense prime short only on valuation dislocation, not as a pure hedge; the short leg should be a lower-volatility name where multiple compression can offset RKLB execution risk.